Updated April 2026 · USPTO + FDA Orange Book
Patent Trend Reports
Data-driven reports highlighting the biggest patent portfolios, looming patent cliffs, and notable movers across 2 ranked datasets — every entity sourced from federal patent records.
What These Reports Show
Each trend report is a ranked snapshot of one signal in the underlying patent data. Snapshots show the current leaderboard for a metric — biggest portfolios, most patents expiring this year, highest Patent Strength Scores. Movement reports compare scores between data refreshes to surface which companies have moved up or down. Aggregates summarize industry-wide totals such as cumulative patents expiring in a given window. The current report set covers 1 snapshot, 0 aggregates, 1 decline tracker, and 0 improvement trackers.
All rankings are built from USPTO patent records pulled through the PatentsView API and cross-referenced with the FDA Orange Book for drug-specific exclusivity timing. No estimates, no proxies — every entity in every report links back to its profile page with the underlying patent list.
How to Read a Report
The headline ranking is the entity list with one metric per row. The metric definition appears in the report subtitle — "150 patents," "27 average claims," or "expiring within 24 months" all map to specific calculations on the underlying USPTO records. The grade column on company-level reports is the Patent Strength Score letter grade (A–F), which combines portfolio size, claims breadth, time remaining, and CPC diversity into a single composite. Click any entity name to see its full patent list and the data that produced its rank.
Rankings are descriptive, not predictive — they tell you what the federal patent record looks like today, not what a portfolio will be worth tomorrow. For investment-grade decisions, cross-reference with company 10-K filings and the underlying methodology.
Available Reports
Biggest Patent Portfolios
Companies with the most patents in key technology areas
Companies Facing Patent Cliffs
Companies with the most patents expiring in the next 2 years
Frequently Asked Questions
What is a trend report on PatentCliff?
A trend report is a ranked list of companies, technologies, or drugs grouped by a single signal in the underlying data — total patent count, share of patents expiring soon, average claims per patent, or movement in Patent Strength Score. Each report is rebuilt from the latest USPTO and FDA Orange Book pulls, so the rankings reflect the most recent federal records rather than a static snapshot.
How often are trend reports updated?
Trend reports are regenerated whenever the underlying patent dataset is refreshed from USPTO PatentsView and the FDA Orange Book. The current generation timestamp is shown alongside each report. Because USPTO publishes weekly and the FDA updates Orange Book listings continuously, reports can shift week to week, especially for rankings driven by expirations within a narrow window.
What does the Patent Strength Score measure?
The Patent Strength Score is a 0–100 composite that blends four signals from a company's portfolio: portfolio size (30%, a proxy for citation depth), claims breadth (25%, the average number of independent claims per patent), time remaining until expiration (25%), and CPC class diversity (20%, how many distinct technology areas the portfolio touches). Letter grades A–F sit on top of the 0–100 score using fixed cutoffs. The score is intended as a relative benchmark across companies tracked here, not an absolute valuation.
Can I use these rankings for investment decisions?
These rankings are research tools, not investment advice. They are useful for screening which companies face the largest near-term patent cliffs or which technologies are seeing growing patent activity, but they do not incorporate sales, margins, pipeline depth, or biosimilar competition risk — all of which matter for valuation. For pharmaceutical-specific exclusivity timing, always cross-reference the underlying USPTO records and the FDA Orange Book before making a decision.
Where does the underlying data come from?
All patent data is sourced from the U.S. Patent and Trademark Office through the PatentsView and Open Data Portal APIs. Drug-specific exclusivity timing is cross-referenced against the FDA Orange Book. Both are public-domain U.S. government datasets. Patent term calculations use the standard 20-year-from-earliest-non-provisional-filing rule, with USPTO-issued Patent Term Adjustments and Patent Term Extensions applied where present in the federal record.
Sources: U.S. Patent and Trademark Office (PatentsView, Open Data Portal); U.S. Food and Drug Administration (Orange Book). Public-domain federal data.
Last updated 2026-04-10 · 2 active trend reports.